Literature DB >> 21752791

A comparative clinical, pathological, biochemical and genetic study of fused in sarcoma proteinopathies.

Tammaryn Lashley1, Jonathan D Rohrer, Rina Bandopadhyay, Charles Fry, Zeshan Ahmed, Adrian M Isaacs, Jack H Brelstaff, Barbara Borroni, Jason D Warren, Claire Troakes, Andrew King, Safa Al-Saraj, Jia Newcombe, Niall Quinn, Karen Ostergaard, Henrik Daa Schrøder, Marie Bojsen-Møller, Hans Braendgaard, Nick C Fox, Martin N Rossor, Andrew J Lees, Janice L Holton, Tamas Revesz.   

Abstract

Neuronal intermediate filament inclusion disease and atypical frontotemporal lobar degeneration are rare diseases characterized by ubiquitin-positive inclusions lacking transactive response DNA-binding protein-43 and tau. Recently, mutations in the fused in sarcoma gene have been shown to cause familial amyotrophic lateral sclerosis and fused in sarcoma-positive neuronal inclusions have subsequently been demonstrated in neuronal intermediate filament inclusion disease and atypical frontotemporal lobar degeneration with ubiquitinated inclusions. Here we provide clinical, imaging, morphological findings, as well as genetic and biochemical data in 14 fused in sarcoma proteinopathy cases. In this cohort, the age of onset was variable but included cases of young-onset disease. Patients with atypical frontotemporal lobar degeneration with ubiquitinated inclusions all presented with behavioural variant frontotemporal dementia, while the clinical presentation in neuronal intermediate filament inclusion disease was more heterogeneous, including cases with motor neuron disease and extrapyramidal syndromes. Neuroimaging revealed atrophy of the frontal and anterior temporal lobes as well as the caudate in the cases with atypical frontotemporal lobar degeneration with ubiquitinated inclusions, but was more heterogeneous in the cases with neuronal intermediate filament inclusion disease, often being normal to visual inspection early on in the disease. The distribution and severity of fused in sarcoma-positive neuronal cytoplasmic inclusions, neuronal intranuclear inclusions and neurites were recorded and fused in sarcoma was biochemically analysed in both subgroups. Fused in sarcoma-positive neuronal cytoplasmic and intranuclear inclusions were found in the hippocampal granule cell layer in variable numbers. Cortical fused in sarcoma-positive neuronal cytoplasmic inclusions were often 'Pick body-like' in neuronal intermediate filament inclusion disease, and annular and crescent-shaped inclusions were seen in both conditions. Motor neurons contained variable numbers of compact, granular or skein-like cytoplasmic inclusions in all fused in sarcoma-positive cases in which brainstem and spinal cord motor neurons were available for study (five and four cases, respectively). No fused in sarcoma mutations were found in any cases. Biochemically, two major fused in sarcoma species were found and shown to be more insoluble in the atypical frontotemporal lobar degeneration with ubiquitinated inclusions subgroup compared with neuronal intermediate filament inclusion disease. There is considerable overlap and also significant differences in fused in sarcoma-positive pathology between the two subgroups, suggesting they may represent a spectrum of the same disease. The co-existence of fused in sarcoma-positive inclusions in both motor neurons and extramotor cerebral structures is a characteristic finding in sporadic fused in sarcoma proteinopathies, indicating a multisystem disorder.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21752791      PMCID: PMC3170529          DOI: 10.1093/brain/awr160

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  40 in total

1.  Maturation process of TDP-43-positive neuronal cytoplasmic inclusions in amyotrophic lateral sclerosis with and without dementia.

Authors:  Fumiaki Mori; Kunikazu Tanji; Hai-Xin Zhang; Yasushi Nishihira; Chun-Feng Tan; Hitoshi Takahashi; Koichi Wakabayashi
Journal:  Acta Neuropathol       Date:  2008-06-17       Impact factor: 17.088

2.  Human POMp75 is identified as the pro-oncoprotein TLS/FUS: both POMp75 and POMp100 DNA homologous pairing activities are associated to cell proliferation.

Authors:  P Bertrand; A T Akhmedov; F Delacote; A Durrbach; B S Lopez
Journal:  Oncogene       Date:  1999-08-05       Impact factor: 9.867

3.  The spectrum and severity of FUS-immunoreactive inclusions in the frontal and temporal lobes of ten cases of neuronal intermediate filament inclusion disease.

Authors:  Richard A Armstrong; Marla Gearing; Eileen H Bigio; Felix F Cruz-Sanchez; Charles Duyckaerts; Ian R A Mackenzie; Robert H Perry; Kari Skullerud; Hedeaki Yokoo; Nigel J Cairns
Journal:  Acta Neuropathol       Date:  2010-10-01       Impact factor: 17.088

4.  FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degeneration.

Authors:  Hazel Urwin; Keith A Josephs; Jonathan D Rohrer; Ian R Mackenzie; Manuela Neumann; Astrid Authier; Harro Seelaar; John C Van Swieten; Jeremy M Brown; Peter Johannsen; Jorgen E Nielsen; Ida E Holm; Dennis W Dickson; Rosa Rademakers; Neill R Graff-Radford; Joseph E Parisi; Ronald C Petersen; Kimmo J Hatanpaa; Charles L White; Myron F Weiner; Felix Geser; Vivianna M Van Deerlin; John Q Trojanowski; Bruce L Miller; William W Seeley; Julie van der Zee; Samir Kumar-Singh; Sebastiaan Engelborghs; Peter P De Deyn; Christine Van Broeckhoven; Eileen H Bigio; Han-Xiang Deng; Glenda M Halliday; Jillian J Kril; David G Munoz; David M Mann; Stuart M Pickering-Brown; Valerie Doodeman; Gary Adamson; Shabnam Ghazi-Noori; Elizabeth M C Fisher; Janice L Holton; Tamas Revesz; Martin N Rossor; John Collinge; Simon Mead; Adrian M Isaacs
Journal:  Acta Neuropathol       Date:  2010-05-20       Impact factor: 17.088

5.  The heritability and genetics of frontotemporal lobar degeneration.

Authors:  J D Rohrer; R Guerreiro; J Vandrovcova; J Uphill; D Reiman; J Beck; A M Isaacs; A Authier; R Ferrari; N C Fox; I R A Mackenzie; J D Warren; R de Silva; J Holton; T Revesz; J Hardy; S Mead; M N Rossor
Journal:  Neurology       Date:  2009-11-03       Impact factor: 9.910

6.  TDP-43-negative FTLD-U is a significant new clinico-pathological subtype of FTLD.

Authors:  Sigrun Roeber; Ian R A Mackenzie; Hans A Kretzschmar; Manuela Neumann
Journal:  Acta Neuropathol       Date:  2008-06-07       Impact factor: 17.088

7.  TDP-43 redistribution is an early event in sporadic amyotrophic lateral sclerosis.

Authors:  Maria Teresa Giordana; Marco Piccinini; Silvia Grifoni; Giovanni De Marco; Marco Vercellino; Michela Magistrello; Alessia Pellerino; Barbara Buccinnà; Elisa Lupino; Maria Teresa Rinaudo
Journal:  Brain Pathol       Date:  2009-03-17       Impact factor: 6.508

8.  Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17.

Authors:  Matt Baker; Ian R Mackenzie; Stuart M Pickering-Brown; Jennifer Gass; Rosa Rademakers; Caroline Lindholm; Julie Snowden; Jennifer Adamson; A Dessa Sadovnick; Sara Rollinson; Ashley Cannon; Emily Dwosh; David Neary; Stacey Melquist; Anna Richardson; Dennis Dickson; Zdenek Berger; Jason Eriksen; Todd Robinson; Cynthia Zehr; Chad A Dickey; Richard Crook; Eileen McGowan; David Mann; Bradley Boeve; Howard Feldman; Mike Hutton
Journal:  Nature       Date:  2006-07-16       Impact factor: 49.962

9.  Frontotemporal lobar degeneration with ubiquitin-only-immunoreactive neuronal changes: broadening the clinical picture to include progressive supranuclear palsy.

Authors:  D C Paviour; A J Lees; K A Josephs; T Ozawa; M Ganguly; C Strand; A Godbolt; R S Howard; T Revesz; J L Holton
Journal:  Brain       Date:  2004-09-30       Impact factor: 13.501

10.  The multifunctional FUS, EWS and TAF15 proto-oncoproteins show cell type-specific expression patterns and involvement in cell spreading and stress response.

Authors:  Mattias K Andersson; Anders Ståhlberg; Yvonne Arvidsson; Anita Olofsson; Henrik Semb; Göran Stenman; Ola Nilsson; Pierre Aman
Journal:  BMC Cell Biol       Date:  2008-07-11       Impact factor: 4.241

View more
  38 in total

1.  Globular glial tauopathies (GGT): consensus recommendations.

Authors:  Zeshan Ahmed; Gabor G Kovacs; Eileen H Bigio; Herbert Budka; Dennis W Dickson; Isidro Ferrer; Bernardino Ghetti; Giorgio Giaccone; Kimmo J Hatanpaa; Janice L Holton; Keith A Josephs; James Powers; Salvatore Spina; Hitoshi Takahashi; Charles L White; Tamas Revesz
Journal:  Acta Neuropathol       Date:  2013-08-31       Impact factor: 17.088

2.  An International Survey of Brain Banking Operation and Characterization Practices.

Authors:  Beatrix Palmer-Aronsten; Donna Sheedy; Toni McCrossin; Jillian Kril
Journal:  Biopreserv Biobank       Date:  2016-07-11       Impact factor: 2.300

Review 3.  Prions, amyloids, and RNA: Pieces of a puzzle.

Authors:  Anton A Nizhnikov; Kirill S Antonets; Stanislav A Bondarev; Sergey G Inge-Vechtomov; Irina L Derkatch
Journal:  Prion       Date:  2016-05-03       Impact factor: 3.931

Review 4.  Fused in Sarcoma Neuropathology in Neurodegenerative Disease.

Authors:  Ian R A Mackenzie; Manuela Neumann
Journal:  Cold Spring Harb Perspect Med       Date:  2017-12-01       Impact factor: 6.915

5.  Frontotemporal lobar degeneration: defining phenotypic diversity through personalized medicine.

Authors:  David J Irwin; Nigel J Cairns; Murray Grossman; Corey T McMillan; Edward B Lee; Vivianna M Van Deerlin; Virginia M-Y Lee; John Q Trojanowski
Journal:  Acta Neuropathol       Date:  2014-12-31       Impact factor: 17.088

6.  Neuronal intermediate filament inclusion disease may be incorrectly classified as a subtype of FTLD-FUS.

Authors:  Kevin F Bieniek; Keith A Josephs; Wen-Lang Lin; Dennis W Dickson
Journal:  Free Neuropathol       Date:  2020-03-11

7.  FUS is phosphorylated by DNA-PK and accumulates in the cytoplasm after DNA damage.

Authors:  Qiudong Deng; Christopher J Holler; Georgia Taylor; Kathryn F Hudson; William Watkins; Marla Gearing; Daisuke Ito; Melissa E Murray; Dennis W Dickson; Nicholas T Seyfried; Thomas Kukar
Journal:  J Neurosci       Date:  2014-06-04       Impact factor: 6.167

8.  Cerebrospinal fluid tau fragment correlates with tau PET: a candidate biomarker for tangle pathology.

Authors:  Kaj Blennow; Chun Chen; Claudia Cicognola; Kristin R Wildsmith; Paul T Manser; Sandra M Sanabria Bohorquez; Zhentao Zhang; Boer Xie; Junmin Peng; Oskar Hansson; Hlin Kvartsberg; Erik Portelius; Henrik Zetterberg; Tammaryn Lashley; Gunnar Brinkmalm; Geoffrey A Kerchner; Robby M Weimer; Keqiang Ye; Kina Höglund
Journal:  Brain       Date:  2020-02-01       Impact factor: 13.501

9.  Requirements for stress granule recruitment of fused in sarcoma (FUS) and TAR DNA-binding protein of 43 kDa (TDP-43).

Authors:  Eva Bentmann; Manuela Neumann; Sabina Tahirovic; Ramona Rodde; Dorothee Dormann; Christian Haass
Journal:  J Biol Chem       Date:  2012-05-04       Impact factor: 5.157

10.  FUS-ALS mutants alter FMRP phase separation equilibrium and impair protein translation.

Authors:  Nicol Birsa; Agnieszka M Ule; Maria Giovanna Garone; Brian Tsang; Francesca Mattedi; P Andrew Chong; Jack Humphrey; Seth Jarvis; Melis Pisiren; Oscar G Wilkins; Micheal L Nosella; Anny Devoy; Cristian Bodo; Rafaela Fernandez de la Fuente; Elizabeth M C Fisher; Alessandro Rosa; Gabriella Viero; Julie D Forman-Kay; Giampietro Schiavo; Pietro Fratta
Journal:  Sci Adv       Date:  2021-07-21       Impact factor: 14.136

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.